Trials / Conditions / Recurrent WHO Grade II Glioma
Recurrent WHO Grade II Glioma
5 registered clinical trials studyying Recurrent WHO Grade II Glioma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Withdrawn | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade G NCT05222165 | Helsinn Healthcare SA | Phase 1 / Phase 2 |
| Active Not Recruiting | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ R NCT04214392 | City of Hope Medical Center | Phase 1 |
| Completed | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations NCT03914742 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Active Not Recruiting | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas NCT03749187 | University of California, San Francisco | Phase 1 |
| Active Not Recruiting | Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma NCT02208362 | City of Hope Medical Center | Phase 1 |